Amlitelimab is safe and effective, with potentially progressive efficacy over time, for patients with moderate-to-severe atopic dermatitis.
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...
On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.
Drugmakers Novo Nordisk and Eli Lilly and Company have transformed the landscape of chronic weight loss management with the ...
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session. Across the COAST 1, COAST 2, and SHORE phase 3 studies ...
The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...
SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results